Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers - Concepedia

Concepedia

Publication | Closed Access

Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers

29

Citations

18

References

2022

Year

Mingxing Hu, Yujue Li, Jiaxuan Li, Haoxuan Zhou, Chengyali Liu, Zi Liu, Youling Gong, Binwu Ying, Yongmei Xie

European Journal of Medicinal Chemistry

MedicinePharmacologyHer2 Positive CancersImproved EfficacyAnti-cancer AgentTumor TargetingCancer TreatmentOncologyCell BiologyDrug Discovery

References

	Year	Citations

Page 1

Page 1